{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-044831","form_type":"8-K","ticker":"DTIL","cik":"0001357874","company_name":"PRECISION BIOSCIENCES INC","filed_at":"2024-04-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.076977+00:00","generated_at":"2026-06-03T22:09:24.104448+00:00","sec_items":["1.02","2.02","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Precision BioSciences loses Lilly/Prevail collaboration; regains DMD, PBGENE-LLY2, PBGENE-LLY3 programs","bullets":["Prevail (Lilly sub) terminated collaboration without cause effective July 10, 2024; Precision exercised reversion option to regain programs.","Collaboration had generated up to $135M upfront; potential milestones up to $390-395M per product plus royalties are now lost.","Preliminary Q1 2024 cash ~$137M; expected cash runway into H2 2026 unaffected (no Prevail milestones assumed).","Precision claims strong proof-of-concept data: up to 45% gene insertion in non-dividing cells in NHP; plans to develop programs independently or with new partners.","Near-term priorities (HBV, PMM, OTC partnership with iECURE) unchanged; IND/CTA submissions on track for 2024-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-044831","json":"https://secwatch.observer/filing/0000950170-24-044831.json","markdown":"https://secwatch.observer/filing/0000950170-24-044831.md","text":"https://secwatch.observer/filing/0000950170-24-044831.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357874/000095017024044831/0000950170-24-044831-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357874/000095017024044831/dtil-20240411.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T22:09:24.104448+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fa2340d83d48b64de0b422922e0b155555be5a55","claim":"PRECISION BIOSCIENCES INC terminated Amended and Restated Development and License Agreement with Prevail Therapeutics Inc. valued at Termination without cause upon 90 days notice (effective 2024-04-11).","evidence_excerpt":"On April 11, 2024, Precision BioSciences, Inc. (the “Company”) received written notice from Prevail Therapeutics Inc. (“Prevail”), a wholly-owned subsidiary of Eli Lilly and Company, of Prevail’s termination of the Amended and Restated Development and License Agreement, dated June 30, 2023, between Prevail and the Company (the “Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1357874/000095017024044831/0000950170-24-044831-index.htm","confidence":0.99,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Prevail Therapeutics Inc."},{"label":"Value","value":"Termination without cause upon 90 days notice"},{"label":"Effective","value":"2024-04-11"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}